DURYSTA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Durysta, and what generic alternatives are available?
Durysta is a drug marketed by Allergan Inc and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and seventy-two patent family members in thirty-two countries.
The generic ingredient in DURYSTA is bimatoprost. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Durysta
A generic version of DURYSTA was approved as bimatoprost by APOTEX INC on December 1st, 2014.
Summary for DURYSTA
| International Patents: | 172 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for DURYSTA |
| What excipients (inactive ingredients) are in DURYSTA? | DURYSTA excipients list |
| DailyMed Link: | DURYSTA at DailyMed |
Pharmacology for DURYSTA
| Drug Class | Prostaglandin Analog |
Anatomical Therapeutic Chemical (ATC) Classes for DURYSTA
US Patents and Regulatory Information for DURYSTA
DURYSTA is protected by nine US patents and one FDA Regulatory Exclusivity.
Patents protecting DURYSTA
Hypotensive lipid-containing biodegradable intraocular implants and related implants
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
Processes for making cyclic lipid implants for intraocular use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Intraocular pressure reduction with intracameral bimatoprost implants
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
Processes for making cyclic lipid implants for intraocular use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Prostamide-containing intraocular implants and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Prostamide-containing intraocular implants and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
FDA Regulatory Exclusivity protecting DURYSTA
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DURYSTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for DURYSTA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH & Co. KG | Lumigan | bimatoprost | EMEA/H/C/000391 Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., |
Authorised | no | no | no | 2002-03-08 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for DURYSTA
See the table below for patents covering DURYSTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2661666 | See Plans and Pricing | |
| Japan | 2016166242 | 眼房内ビマトプロスト注入物による眼圧低下 (INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS) | See Plans and Pricing |
| Hungary | E033186 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DURYSTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | C300099 | Netherlands | See Plans and Pricing | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308 |
| 0660716 | 02C0033 | France | See Plans and Pricing | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| 0660716 | SPC/GB02/035 | United Kingdom | See Plans and Pricing | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
